210 related articles for article (PubMed ID: 23390522)
1. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.
Massoner P; Kugler KG; Unterberger K; Kuner R; Mueller LA; Fälth M; Schäfer G; Seifarth C; Ecker S; Verdorfer I; Graber A; Sültmann H; Klocker H
PLoS One; 2013; 8(2):e55207. PubMed ID: 23390522
[TBL] [Abstract][Full Text] [Related]
2. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
Rickman DS; Chen YB; Banerjee S; Pan Y; Yu J; Vuong T; Perner S; Lafargue CJ; Mertz KD; Setlur SR; Sircar K; Chinnaiyan AM; Bismar TA; Rubin MA; Demichelis F
Neoplasia; 2010 Dec; 12(12):1031-40. PubMed ID: 21170267
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
[TBL] [Abstract][Full Text] [Related]
4. V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application.
Park K; Chiu YL; Rubin MA; Demichelis F; Mosquera JM
Hum Pathol; 2013 Oct; 44(10):2282-92. PubMed ID: 23856515
[TBL] [Abstract][Full Text] [Related]
5. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.
Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J
Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
Alshalalfa M; Nguyen PL; Beltran H; Chen WS; Davicioni E; Zhao SG; Rebbeck TR; Schaeffer EM; Lotan TL; Feng FY; Mahal BA
Eur Urol Oncol; 2019 Jul; 2(4):405-412. PubMed ID: 31164324
[TBL] [Abstract][Full Text] [Related]
7. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
Tomlins SA; Rhodes DR; Yu J; Varambally S; Mehra R; Perner S; Demichelis F; Helgeson BE; Laxman B; Morris DS; Cao Q; Cao X; Andrén O; Fall K; Johnson L; Wei JT; Shah RB; Al-Ahmadie H; Eastham JA; Eggener SE; Fine SW; Hotakainen K; Stenman UH; Tsodikov A; Gerald WL; Lilja H; Reuter VE; Kantoff PW; Scardino PT; Rubin MA; Bjartell AS; Chinnaiyan AM
Cancer Cell; 2008 Jun; 13(6):519-28. PubMed ID: 18538735
[TBL] [Abstract][Full Text] [Related]
8. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
[TBL] [Abstract][Full Text] [Related]
9. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
10. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract][Full Text] [Related]
11. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
Vainio P; Gupta S; Ketola K; Mirtti T; Mpindi JP; Kohonen P; Fey V; Perälä M; Smit F; Verhaegh G; Schalken J; Alanen KA; Kallioniemi O; Iljin K
Am J Pathol; 2011 Feb; 178(2):525-36. PubMed ID: 21281786
[TBL] [Abstract][Full Text] [Related]
12. Antibody-based detection of ERG rearrangement-positive prostate cancer.
Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
[TBL] [Abstract][Full Text] [Related]
13. ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.
Kacprzyk LA; Laible M; Andrasiuk T; Brase JC; Börno ST; Fälth M; Kuner R; Lehrach H; Schweiger MR; Sültmann H
PLoS One; 2013; 8(3):e59976. PubMed ID: 23555854
[TBL] [Abstract][Full Text] [Related]
14. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
15. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
16. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.
Gao X; Li LY; Zhou FJ; Xie KJ; Shao CK; Su ZL; Sun QP; Chen MK; Pang J; Zhou XF; Qiu JG; Wen XQ; Yang M; Bai XZ; Zhang H; Ling L; Chen Z
Clin Cancer Res; 2012 Aug; 18(15):4163-72. PubMed ID: 22696228
[TBL] [Abstract][Full Text] [Related]
17. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer.
Kristensen G; Røder MA; Berg KD; Elversang J; Iglesias-Gato D; Moreira J; Toft BG; Brasso K
APMIS; 2018 Oct; 126(10):804-813. PubMed ID: 30191621
[TBL] [Abstract][Full Text] [Related]
20. ERG gene rearrangements are common in prostatic small cell carcinomas.
Lotan TL; Gupta NS; Wang W; Toubaji A; Haffner MC; Chaux A; Hicks JL; Meeker AK; Bieberich CJ; De Marzo AM; Epstein JI; Netto GJ
Mod Pathol; 2011 Jun; 24(6):820-8. PubMed ID: 21336263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
